Clinical drug

lazertinib 80 MG Oral Tablet [Lazcluze]

80 MG · Oral Tablet · oral

A form of lazertinib

lazertinib 80 MG Oral Tablet [Lazcluze] — Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Strength, form, class, interactions & more.

lazertinib 80 MG Oral Tablet [Lazcluze]

Active ingredient

Classification

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsKinase Inhibitor

Drug interactions

Lazertinib has several interactions with CYP3A4 and BCRP substrates and inducers.

  • majorstrong and moderate CYP3A4 inducers — decreased lazertinib concentrations, which may reduce efficacy
  • moderateCYP3A4 substrates — increased concentrations of CYP3A4 substrates, which may increase the risk of adverse reactions
  • moderateBCRP substrates — increased concentrations of BCRP substrates, which may increase the risk of adverse reactions

Real-world adverse events (FAERS)

Rash114Infusion Related Reaction68Neuropathy Peripheral36Fatigue35Off Label Use33Paronychia33Diarrhoea29Dyspnoea24

Source: RxNorm + openFDA + RxClass + FAERS · 2026

Look up another medication

Powered by Eleplan

A drug lookup is just the start. Eleplan keeps the whole care plan in one place.

Medications, diagnoses, documents, appointments, and the whole care team — organized and always in sync, with Ellie, your AI care assistant, on top of it. Free to start.